stockrowBeOne Medicines Ltd. - Sponsored ADR
BeOne Medicines Ltd. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.3 billion, up 40.2% from fiscal 2024.
- Revenue
- +33.8%
- EPS
- +143.7%
- Free cash flow
- +33.6%
- Total debt
- +491.3%
Quarter to September 2026, against a year earlier
Follow ONC
Alert me
BeOne Medicines Ltd. - Sponsored ADR (ONC) Return on assets
BeOne Medicines Ltd. - Sponsored ADR's return on assets over the twelve months to 30 September 2026 was 10.5%, up 6.4 percentage points from fiscal 2025 (4.07%). Over the past ten years it has ranged from −67.0% (fiscal 2015) to 4.07% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 4.07% | 15.07 |
| FY2024 | −11.0% | 3.47 |
| FY2023 | −14.5% | 12.40 |
| FY2022 | −26.9% | (6.24) |
| FY2021 | −20.6% | 23.65 |
| FY2020 | −44.3% | 4.85 |
| FY2019 | −49.1% | (8.25) |
| FY2018 | −40.9% | (28.06) |
| FY2017 | −12.8% | 32.81 |
| FY2016 | −45.6% | 21.40 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ONC BeOne Medicines Ltd. - Sponsored ADR | 10.5% |
| GMAB Genmab A/S Sponsored ADR compare | 8.30% |
| INCY Incyte Corporation compare | 5.92% |
| ARGX argenex SE compare | 0.00% |
| RPRX Royalty Pharma PLC compare | 0.00% |
| ROIV Roivant Sciences Ltd. compare | −5.15% |
| BNTX BioNTech SE Sponsored ADR compare | −7.22% |
| INSM Insmed, Inc. compare | −26.4% |
| RVMD Revolution Medicines, Inc. compare | −57.1% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on ONC
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement